1.0EASOhttps://easo.org/frrich600338<blockquote class="wp-embedded-content" data-secret="sCjdDLjNQD"><a href="https://easo.org/fr/new-research-presented-live-at-eco/">Nouvelle recherche présentée en direct à ECO</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://easo.org/fr/new-research-presented-live-at-eco/embed/#?secret=sCjdDLjNQD" width="600" height="338" title="“New Research presented live at ECO” — EASO" data-secret="sCjdDLjNQD" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://easo.org/wp-includes/js/wp-embed.min.js </script>https://easo.org/wp-content/uploads/2025/05/new-research-presented.jpg700400A new head-to-head study of tirzepatide versus semaglutide for weight loss in people living with obesity, but not diabetes, shows that over 72 weeks tirzepatide results in an average weight loss of 20.2%, 47% higher than the 13.7% average weight loss for semaglutide. The study, presented at this year’s European Congress on Obesity in Malaga, […]